Hypofractionated Salvage Radiation Shows No Superiority Over Standard Care in Prostate Cancer Trial
A phase 3 trial in South Korea found that accelerated hypofractionated salvage radiotherapy offers no better cancer control than standard treatment for patients with biochemical recurrence after prostatectomy, though it carries a higher risk of late gastrointestinal side effects.